undamentalytics Newsletter
Sign in

Inspiremd, Inc. (NSPR) stock

Add to watchlist

Add holding +

NASDAQ: NSPR Nasdaq Health Care Equipment Next results ~November 12, 2026

D Fundamentals grade

Inspiremd, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.6

Valuation models combined (2)

Base case. Range ~$0.5–$0.6. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Inspiremd, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 1 selling18 purchases and 12 sales by directors and officers, last 12 monthsInsider trades
  • Funds17 adding, 9 cuttingOf 6 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Inspiremd files

Where Inspiremd stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $11m, up 53.4% on a year earlier, slower than the 54.4% growth a quarter earlier. Free-cash-flow margin rose to -391.7% from -442.1% a year earlier. Operating margin widened to -494.0% from -598.8%. The diluted share count is up 63.5% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $0.12 a share, against a share price of $0.45.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Inspiremd, Inc.'s trailing-twelve-month revenue grew 53.4% year on year, with a free-cash-flow margin of -391.7%. Where it stands out: revenue growth of 53.4% ranks 10 of 129 health care equipment companies we cover. Where it lags: change in share count of 63.5% ranks 109 of 115 health care equipment companies we cover.

Current signal Share count rising (dilution): Diluted shares outstanding rose 63.5% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 53.4% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 104.7 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -494.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -391.7% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 98.8% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 63.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 68% and a beta of 0.8 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$0.17 against an average estimate of -$0.20: beat by 15.0%
Revenue
$2m, down 0.4% on a year earlier
Share reaction
-10.2% in the first session after the results on August 17, 2026, against -1.1% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.15

Inspiremd's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+20.0%
  • 1 week+20.0%
  • 1 month-12.9%
  • This year-69.7%
  • 1 year-75.6%
  • 5 years-87.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$10.8M
Operating margin
-494.0%
Net margin
-484.1%
EPS (TTM, diluted)
$-0.65

Growth

Revenue growth
+53.4%
Change in growth rate
−1.0 pts
Share count change
+63.5%

Cash

Free cash flow (TTM)
-$42.5M
FCF margin
-391.7%
Stock pay % of revenue
98.8%

Earnings

Last results
August 17, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Inspiremd, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Inspiremd, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 7.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.67 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.6 ~$0.3–$1.0 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.5 ~$0.6–$2.0 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.6 ~$0.5–$0.6 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Inspiremd, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$577500.00$65625.00$3412.50$120.00$16.20$5.10$3.02$0.86$2.81$2.63$1.78$0.54
Market value$2.42tn$40.1bn$19.1bn$831m$508m$116m$67m$20m$68m$110m$114m$44m
+ Net debt (− = net cash)$2m−$8m−$4m−$9m−$6m−$13m−$12m−$5m−$10m−$19m−$9m−$15m
Enterprise value$2.42tn$40.1bn$19.1bn$821m$502m$103m$55m$16m$59m$91m$106m$29m
Multiples
Price / sales n/mn/mn/mn/m136.5x46.6x14.8x3.9x11.0x15.7x12.8x4.0x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ———————0.1x0.3x0.4x0.2x0.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

18 /100

Weak moat

How hard Inspiremd's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -61.2% of total assets over 10 years.

  • Pricing power 4 / 20

    Gross margin has been a median 19.6%, moving by 6.0 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -379.0%; its worst year was -598.8%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -309.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $2m and EPS of −$0.15 (range −$0.16 to −$0.15) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.45 +40% $10m +9%
Next −$0.48 −7% $20m +105%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −38.7% on 90 days ago. In the last 30 days, 2 analysts raised Inspiremd, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Inspiremd, Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.74 Current fiscal year, 60 days ago: −$0.74 Current fiscal year, 30 days ago: −$0.74 Current fiscal year, 7 days ago: −$0.74 Current fiscal year, Now: −$0.45 −$0.45 Next fiscal year, 90 days ago: −$0.61 Next fiscal year, 60 days ago: −$0.61 Next fiscal year, 30 days ago: −$0.61 Next fiscal year, 7 days ago: −$0.61 Next fiscal year, Now: −$0.48 −$0.48

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.74−$0.61
60 days ago −$0.74−$0.61
30 days ago −$0.74−$0.61
7 days ago −$0.74−$0.61
Now −$0.45−$0.48

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.20 −$0.17 +15.0%
Mar 2026 −$0.18 −$0.16 +11.1%
Dec 2025 −$0.19 −$0.14 +27.6%
Sept 2025 −$0.20 −$0.17 +12.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026213
  2. Sep 2026213

Counts of recommendations published by analysts covering Inspiremd, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.2%
of tradable shares
Days to cover
0.75
at average volume
Short interest, 1 month
+219%
to October 15, 2026
Held by institutions
46%
of shares
Held by insiders
20.0%
of shares
Employees
127
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NSPR−41%−72%+227%−6%−32%−70%
Industry peers (median)−7%−37%−9%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NSPR25%25%58%33%25%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NSPR−85%−75%−45%−41%−56%−77%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 4, 2015 to October 19, 2026. Getting back needed a 162570923% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.44 – $2.29
From 52-week high
−76.4%
vs 50-day average
−17.8%
vs 200-day average
−49.3%
Volatility (1 year)
68%
Beta vs S&P 500
0.80

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±4.3%
After a week
3 up, 9 down
typical move ±7.2%
After a month
2 up, 10 down
typical move ±13.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 17, 2026 −10.2% −1.1% −11.2% −21.4%
May 4, 2026 −4.3% +0.4% +8.7% −16.5%
March 18, 2026 −4.5% −1.6% −1.1% −24.6%
November 4, 2025 −7.9% −0.8% −28.8% −16.2%
August 5, 2025 −6.4% +0.3% −5.6% −8.6%
May 9, 2025 −0.8% +3.2% −9.2% −6.2%
March 12, 2025 +2.9% −0.8% +0.4% −4.7%
August 6, 2024 −3.4% +0.2% −0.3% −7.4%
May 14, 2024 −4.2% +1.7% −2.9% +8.3%
March 6, 2024 +0.4% +1.5% −4.9% −12.9%
November 6, 2023 −6.1% +0.5% −11.3% −26.1%
August 8, 2023 0.0% −1.1% +1.9% +11.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Inspiremd, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Inspiremd, Inc.
$4M $6M $8M $10M $12M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $5.5M Revenue (TTM), FY23 Q4: $6.2M Revenue (TTM), FY24 Q1: $6.5M Revenue (TTM), FY24 Q2: $6.6M Revenue (TTM), FY24 Q3: $6.8M Revenue (TTM), FY24 Q4: $7M Revenue (TTM), FY25 Q1: $7M Revenue (TTM), FY25 Q2: $7.1M Revenue (TTM), FY25 Q3: $7.8M Revenue (TTM), FY25 Q4: $9M Revenue (TTM), FY26 Q1: $10.8M Revenue (TTM), FY26 Q2: $10.8M $10.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $5.5M
FY23 Q4 $6.2M
FY24 Q1 $6.5M
FY24 Q2 $6.6M
FY24 Q3 $6.8M
FY24 Q4 $7M
FY25 Q1 $7M
FY25 Q2 $7.1M
FY25 Q3 $7.8M
FY25 Q4 $9M
FY26 Q1 $10.8M
FY26 Q2 $10.8M
Revenue growth, TTM YoY Inspiremd, Inc.
-20% 0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -1.0% Revenue growth, TTM YoY, FY23 Q4: 20.0% Revenue growth, TTM YoY, FY24 Q1: 23.9% Revenue growth, TTM YoY, FY24 Q2: 22.9% Revenue growth, TTM YoY, FY24 Q3: 24.7% Revenue growth, TTM YoY, FY24 Q4: 13.0% Revenue growth, TTM YoY, FY25 Q1: 8.5% Revenue growth, TTM YoY, FY25 Q2: 7.6% Revenue growth, TTM YoY, FY25 Q3: 14.0% Revenue growth, TTM YoY, FY25 Q4: 28.1% Revenue growth, TTM YoY, FY26 Q1: 54.4% Revenue growth, TTM YoY, FY26 Q2: 53.4% 53.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -1.0%
FY23 Q4 20.0%
FY24 Q1 23.9%
FY24 Q2 22.9%
FY24 Q3 24.7%
FY24 Q4 13.0%
FY25 Q1 8.5%
FY25 Q2 7.6%
FY25 Q3 14.0%
FY25 Q4 28.1%
FY26 Q1 54.4%
FY26 Q2 53.4%
Operating margin (TTM) Inspiremd, Inc.
-800% -600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -370.6% Operating margin (TTM), FY23 Q4: -340.7% Operating margin (TTM), FY24 Q1: -373.3% Operating margin (TTM), FY24 Q2: -413.0% Operating margin (TTM), FY24 Q3: -439.0% Operating margin (TTM), FY24 Q4: -478.0% Operating margin (TTM), FY25 Q1: -534.4% Operating margin (TTM), FY25 Q2: -598.8% Operating margin (TTM), FY25 Q3: -602.9% Operating margin (TTM), FY25 Q4: -552.6% Operating margin (TTM), FY26 Q1: -480.6% Operating margin (TTM), FY26 Q2: -494.0% -494.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -370.6%
FY23 Q4 -340.7%
FY24 Q1 -373.3%
FY24 Q2 -413.0%
FY24 Q3 -439.0%
FY24 Q4 -478.0%
FY25 Q1 -534.4%
FY25 Q2 -598.8%
FY25 Q3 -602.9%
FY25 Q4 -552.6%
FY26 Q1 -480.6%
FY26 Q2 -494.0%
FCF margin (TTM) Inspiremd, Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -286.2% FCF margin (TTM), FY23 Q4: -270.1% FCF margin (TTM), FY24 Q1: -264.9% FCF margin (TTM), FY24 Q2: -283.5% FCF margin (TTM), FY24 Q3: -302.0% FCF margin (TTM), FY24 Q4: -332.0% FCF margin (TTM), FY25 Q1: -386.5% FCF margin (TTM), FY25 Q2: -442.1% FCF margin (TTM), FY25 Q3: -438.1% FCF margin (TTM), FY25 Q4: -409.5% FCF margin (TTM), FY26 Q1: -370.1% FCF margin (TTM), FY26 Q2: -391.7% -391.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -286.2%
FY23 Q4 -270.1%
FY24 Q1 -264.9%
FY24 Q2 -283.5%
FY24 Q3 -302.0%
FY24 Q4 -332.0%
FY25 Q1 -386.5%
FY25 Q2 -442.1%
FY25 Q3 -438.1%
FY25 Q4 -409.5%
FY26 Q1 -370.1%
FY26 Q2 -391.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-KT, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Jun 2012 2013 Jun 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 3 5 6 5 5 3 2 2 3 4 4 2 4 5 6 7 9 11
Gross profit 1 2 3 3 3 1 −0 0 1 1 1 0 1 1 2 2 3 2
EBITDA −3 −3 −14 −17 −15 −23 −14 −8 −8 −7 −10 −10 −15 169 211 246 426 423
Operating income −3 −3 −14 −18 −15 −24 −14 −8 −8 −8 −10 −10 −15 −19 −21 −34 −50 −54
Net income −3 −3 −15 −18 −29 −25 −16 −8 −8 −7 −10 −11 −15 −18 −20 −32 −49 −52
Diluted EPS −$0.00 −$0.00 −$30.00 −$8.67 −$11.58 −$5.91 −$3.72 −$13.85 −$2.33 −$1.11 −$0.32 −$0.46 −$0.68 −$0.78 −$0.82 −$0.76 −$0.76 −$0.65
Growth (year on year)
Revenue — +45.1% +21.3% −10.9% −8.9% −42.2% −18.0% −18.0% +45.8% +30.4% +3.3% −33.2% +80.9% +15.0% +20.0% +13.0% +28.1% +53.4%
EBITDA — — — — — — — — — — — — — — +24.6% +16.9% +73.0% +77.7%
Margins
Gross margin 32.8% 45.5% 49.9% 46.7% 53.1% 27.8% −12.8% 5.4% 21.2% 27.6% 20.3% 3.3% 16.8% 21.6% 29.1% 21.5% 29.5% 18.1%
EBITDA margin −77.0% −63.2% −227.2% −325.8% −305.0% −831.6% −620.5% −396.3% −292.6% −207.5% −259.6% −411.6% −323.8% >999% >999% >999% >999% >999%
Operating margin −79.7% −65.0% −228.7% −328.0% −309.3% −841.0% −627.1% −403.8% −298.2% −211.4% −263.8% −417.7% −327.4% −361.9% −340.7% −478.0% −552.6% −494.0%
Net margin −79.9% −69.1% −244.3% −329.0% −600.4% −890.5% −674.7% −446.7% −305.6% −201.1% −269.8% −424.3% −331.9% −357.6% −321.0% −456.6% −543.3% −484.1%
Free-cash-flow margin −46.3% −56.4% −102.3% −165.8% −215.5% −691.8% −502.7% −398.3% −303.8% −213.1% −271.3% −369.0% −301.5% −309.7% −270.1% −332.0% −409.5% −391.7%
Cash flow
Cash from operations −2 −3 −6 −9 −10 −19 −12 −7 −8 −8 −10 −9 −13 −16 −16 −22 −35 −41
Capital spending 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1
Free cash flow −2 −3 −6 −9 −11 −19 −12 −8 −8 −8 −10 −9 −14 −16 −17 −23 −37 −42
Stock-based pay 1 2 10 11 4 4 3 1 1 0 0 1 2 2 4 10 12 11
Free cash flow after stock pay −2 −4 −16 −19 −14 −24 −15 −9 −9 −8 −10 −10 −15 −18 −21 −33 −49 −53
Balance sheet
Cash 0 1 5 — — 6 3 8 4 9 6 13 12 5 10 19 9 15
Total debt 0 1 — 5 — 9 5 — 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −0 1 −5 — — 3 2 −8 −4 −9 −6 −13 −12 −5 −10 −19 −9 −15
Diluted shares — — — 2,005m 3m 4m 4m — 6m 7m 31m 23m 22m 24m 24m 42m 64m 81m
Returned to shareholders
Buybacks — — — 0 — — — — — — — — — — — — — —
Total returned — — — 0 — — — — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $45m
Short-term assets $37mLonger-term assets $8m
What it owes, and who funded it · $45m
Short-term liabilities $10mLonger-term liabilities $3mShareholders' equity $32m
  • Short-term assets cover short-term liabilities $37m of assets due within a year against $10m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $37m short-term assets against $3m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Inspiremd, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+63.5%
year over year
R&D spending
149.1%
of revenue
Days sales outstanding
61 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated NSPR WOK HSDT NMTC MLSS NNOX Median
Revenue, last 12 months $11m $10m $12m $9m $9m $13m $99m
Revenue growth, last 12 months 53.4% −14.4% >999% 42.8% 3.7% 15.4% 9.2%
Revenue growth, 3-year average 26.6% — 142.6% 94.9% −1.9% — 13.5%
Revenue growth, latest quarter −0.4% — >999% 16.3% 22.3% — 10.2%
Gross margin 18.1% 23.8% 95.5% 55.6% 70.2% −98.2% 61.2%
Operating margin −494.0% — <−999% −83.4% −43.6% −600.8% −8.5%
Operating margin, 3-year average −501.9% — <−999% −160.3% −66.8% — −17.9%
Net margin −484.1% −10.9% <−999% −78.6% −44.0% −576.1% −12.0%
Cash from operations / revenue −380.1% 63.4% −223.2% −74.5% −6.8% −313.3% −1.9%
Free-cash-flow margin −391.7% 49.9% −223.2% −75.6% −7.0% −345.6% −3.9%
Free-cash-flow margin, 3-year average −372.4% — <−999% −142.5% −53.1% — −7.0%
Stock pay / revenue 98.8% — 69.3% 14.9% 10.3% 32.2% 6.1%
Change in share count 63.5% 128.1% >999% 41.1% 5.9% 10.4% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 53.4% 9.1% 10 of 129
Change in growth rate Growth -1.0pp -0.6pp 73 of 129
Gross margin Profitability 18.1% 61.9% 113 of 123
Operating margin Profitability -494.0% -8.3% 115 of 132
Net margin Profitability -484.1% -12.0% 116 of 133
Free-cash-flow margin Cash generation -391.7% -3.4% 114 of 128
Stock pay as % of revenue Cash generation 98.8% 6.1% 114 of 123
Change in share count Balance sheet 63.5% 3.3% 109 of 115
Days sales outstanding Balance sheet 61 days 57 days 70 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
Other Countries $4.1M 45.2% ▲ 18.7%
United States $1.4M 15.8% ▲ 4328.1%
Germany $1.2M 13.7% ▲ 33.2%
IT $1.2M 13.7% ▲ 0.7%
PL $1M 11.5% ▲ 49.3%

From Inspiremd, Inc.'s 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$17.4M
Institutions reporting
36
Shares held vs prior quarter
▲ 9.4%
Positions opened / closed
7 / 4

Top buyers and sellers, Q2 2026: 17 institutions bought and 9 sold ; the biggest buyer was Nantahala Capital Management, LLC (+3.4M shares) and the biggest seller Velan Capital Investment Management LP (−2.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $4.7M 6.8M 27.1% ▲ 100.0%
Rosalind Advisors, Inc. $2.7M 3.9M 15.7% 0.0%
Aberdeen Group PLC $2.6M 3.7M 14.8% ▲ 16.5%
Orbimed Advisors LLC $2.2M 3.1M 12.6% 0.0%
Parkman Healthcare Partners LLC $1.7M 2.4M 9.7% 0.0%
Marshall Wace, LLP $1.3M 1.9M 7.5% 0.0%
Soleus Capital Management, L.P. $732,100 1.0M 4.2% 0.0%
Pura Vida Investments, LLC $315,407 451K 1.8% 0.0%
Ingalls & Snyder LLC $258,000 369K 1.5% ▼ 2.8%
Affiance Financial, LLC $175,284 250K 1.0% 0.0%
Velan Capital Investment Management LP $103,711 148K 0.6% ▼ 92.9%
Blackrock, Inc. $86,108 123K 0.5% ▲ 52.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Inspiremd, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $518,095 18 trades by 4 insiders, last 12 months Insider sales History → $126,870 12 trades by 1 insider · 0% under pre-set plans
Net ▲ $391,225 net buying
Insider Date Trade Shares Price Value
Stuka Paul Director May 27, 2026 Buy 20,000 $0.88 $17,600
Gleason Shane Thomas Chief Commercial Officer May 19, 2026 Sell 22,778 $1.01 $23,006
Stuka Paul Director May 14, 2026 Buy 5,000 $1.15 $5,750
Stuka Paul Director May 13, 2026 Buy 10,000 $1.16 $11,600
Slosman Marvin CEO and President May 12, 2026 Buy 21,000 $1.20 $25,200
Stuka Paul Director May 11, 2026 Buy pre-set plan 10,000 $1.19 $11,900
Stuka Paul Director May 11, 2026 Buy pre-set plan 10,000 $1.19 $11,900
Stuka Paul Director May 8, 2026 Buy pre-set plan 65,626 $1.16 $76,126
Stuka Paul Director May 8, 2026 Buy pre-set plan 65,626 $1.16 $76,126
Roubin Gary S Director May 7, 2026 Buy 90,000 $1.18 $106,200
Stuka Paul Director May 7, 2026 Buy 6,378 $1.15 $7,335
Ward Scott R. Director May 7, 2026 Buy 73,255 $1.15 $84,243

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 17, 2026
  • May 4, 2026
  • March 18, 2026
  • November 4, 2025
  • August 5, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on Inspiremd, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Inspiremd, Inc. in brief

What does Inspiremd, Inc. do?
Inspiremd, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Inspiremd, Inc.'s stock ticker?
Inspiremd, Inc. trades under the ticker NSPR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Inspiremd, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Inspiremd, Inc. reported revenue of $10.8M, 53.4% higher than a year earlier, according to its SEC filings.
What is Inspiremd, Inc.'s free cash flow?
Inspiremd, Inc.'s free-cash-flow margin is -391.7% of revenue over the trailing twelve months, ranking 114 of the 128 health care equipment companies we cover.
Who are Inspiremd, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Rosalind Advisors, Inc. and Aberdeen Group PLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Inspiremd, Inc.'s market cap?
On November 2, 2026, Inspiremd, Inc.'s market capitalisation was about $43.8M and net debt of -$15.1M. Market figures come from third-party market data and may be delayed.
Who are Inspiremd, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Inspiremd, Inc. are Work Medical Technology Group LTD, Solana Co, Neuroone Medical Technologies Corp, Milestone Scientific Inc. and Nano-x Imaging Ltd. The side-by-side comparison below sets their revenue, margins and growth against Inspiremd, Inc.'s.
Are insiders buying or selling Inspiremd, Inc. stock?
Over the last 12 months, Inspiremd, Inc.'s directors and officers reported 18 open-market purchases and 12 sales on Form 4. The insider trading page charts every trade.
When is Inspiremd, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Inspiremd, Inc. announces its own schedule.